MTLN:LSEMetlen Energy & Metals PLC Analysis
Data as of 2026-07-03 - not real-time
€41.86
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Metlen Energy & Metals PLC traded at €41.86, marginally above its 20‑day SMA of €41.21 and 200‑day SMA of €40.57, indicating short‑term price strength. However, the MACD histogram is negative (‑0.08) and the signal line is bearish, suggesting momentum may be waning. RSI sits at 55, well below overbought levels, leaving room for further upside. The stock faces a clear support at €39.5 and resistance near €42.8, a narrow range that could trap traders. Volume is on an increasing trend, providing liquidity for position adjustments. Fundamentally, the company posted €7.1 bn revenue with 9.3% growth YoY and a modest profit margin of 4.4%.
Operating margin remains negative (‑1.6%) and free cash flow is –€0.9 bn, highlighting cash‑generation concerns. Leverage is high, with a debt‑to‑equity of 164% and total debt of €5.1 bn, while the beta of 0.23 points to low market sensitivity. The current PE of 19x is below the industry average of 21x, and the forward PE collapses to 8x, reflecting strong earnings expectations. The DCF fair value of €19.25 is far below the market price, flagging potential overvaluation, yet analysts rate the stock a “strong buy” with a median target of €53.5, implying ~28% upside. The dividend yield of 2.37% appears attractive, but a payout ratio of 0 and negative free cash flow raise sustainability questions. Recent news of record 2026 turnover and a €2 bn earnings target underscores the company’s growth narrative and could support the upside case.
Operating margin remains negative (‑1.6%) and free cash flow is –€0.9 bn, highlighting cash‑generation concerns. Leverage is high, with a debt‑to‑equity of 164% and total debt of €5.1 bn, while the beta of 0.23 points to low market sensitivity. The current PE of 19x is below the industry average of 21x, and the forward PE collapses to 8x, reflecting strong earnings expectations. The DCF fair value of €19.25 is far below the market price, flagging potential overvaluation, yet analysts rate the stock a “strong buy” with a median target of €53.5, implying ~28% upside. The dividend yield of 2.37% appears attractive, but a payout ratio of 0 and negative free cash flow raise sustainability questions. Recent news of record 2026 turnover and a €2 bn earnings target underscores the company’s growth narrative and could support the upside case.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram and signal line
- Price approaching short‑term resistance at €42.8
- High 30‑day volatility (~36%)
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward PE of 8x indicating strong earnings upside
- Analyst consensus strong‑buy with median target €53.5
- Record 2026 turnover and €2 bn earnings target
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Diversified utilities‑diversified sector provides stability
- High leverage (debt‑to‑equity >160%) and negative free cash flow
- Low beta (0.23) suggests limited market‑wide risk
Key Metrics & Analysis
Financial Health
Revenue Growth9.30%
Profit Margin4.42%
P/E Ratio19.0
ROE10.48%
ROA1.76%
Debt/Equity163.85
P/B Ratio2.0
Op. Cash Flow€445.9M
Free Cash Flow€-905411968
Industry P/E21.1
Technical Analysis
TrendNeutral
RSI55.2
Support€39.50
Resistance€42.80
MA 20€41.21
MA 50€39.37
MA 200€40.57
MACDBearish
VolumeIncreasing
Fear & Greed Index92.59
Valuation
Fair Value€19.25
Target Price€53.50
Upside/Downside27.81%
GradeFair
TypeGrowth
Dividend Yield2.37%
Risk Assessment
Beta0.23
Volatility35.91%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.